bioAffinity highlights CyPath Lung at CHEST 2026
Detailed price information for Bioaffinity Technologies Inc (BIAF-Q) from The Globe and Mail including charting and trades.
Model output · Signal date 2026-10-16
Bioaffinity Technologies, Inc. (BIAF) Stock Forecast Oct. 16, 2026
Analysis updated on Oct. 16, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq
Rating · 90D
▼ Bearish
Exact rating locked
90-day forecast
Sign up free to reveal
30-day forecast
Alpha
Rank in coverage
Bottom 35%
of 5172 stocks scored
Rank correlation · 90D
18.0%
Spearman, 341 dates
Market Cap
$5M
small-cap · #12 of 15 peers
Summary
Bioaffinity Technologies, Inc. (BIAF) stock forecast summary
Our AI ranks Bioaffinity Technologies, Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
Bioaffinity Technologies, Inc. is a small-cap company with a market capitalization of $5M. It ranks number 12 by market capitalization among the 15 Services-Commercial Physical & Biological Research issuers in our coverage with a current forecast. Its ROE of -402.9% is the lowest of the 9 peers that report one.
For BIAF, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 18.0%, measured on 341 forecast dates between 2022-11-18 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 19.0%, measured on 384 forecast dates between 2022-11-18 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.8%, buy ≥ +0.2%, sell < -0.9%, strong sell < -1.2% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-16 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, BIAF included.
Follow BIAF freePrice
BIAF price chart and AI forecast
Cross-section · 2026-10-16
How BIAF ranks among 5172 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Fundamentals · 2026-06-30
Bioaffinity Technologies, Inc. (BIAF) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Services-Commercial Physical & Biological Research peers listed below that report each metric.
Valuation & Market
| Metric | BIAF | Rank |
|---|---|---|
| Market Cap | $5M | 12/15 |
| P/B Ratio | 1.27x | 9/10 |
| EPS | $-9.13 | – |
| Book Value/Share | $2.93 | – |
| Revenue/Share | $4.60 | – |
| FCF/Share | $-9.00 | – |
Profitability & Margins
| Metric | BIAF | Rank |
|---|---|---|
| ROE | -402.9% | 9/9 |
| ROA | -199.3% | 9/11 |
| Operating Margin | -209.8% | 9/13 |
| Net Margin | -257.3% | 8/10 |
| EBT Margin | -257.2% | 9/13 |
| Tax Rate | -0.3% | – |
Financial Health
| Metric | BIAF | Rank |
|---|---|---|
| Current Ratio | 1.44x | 5/16 |
| Quick Ratio | 1.41x | 4/6 |
| D/E Ratio | 1.02x | 6/11 |
| Financial Leverage | 2.02x | 6/10 |
| Interest Coverage | -249.2x | 9/13 |
| Working Capital | $1M | 6/15 |
Cash Flow
| Metric | BIAF | Rank |
|---|---|---|
| Operating Cash Flow | -$11M | 12/15 |
| Free Cash Flow | -$12M | 4/7 |
| Capital Spending | -$90K | 1/7 |
| FCF/Sales | -195.9% | 7/8 |
| CapEx/Sales | 1.6% | 7/8 |
Operational Efficiency
| Metric | BIAF | Rank |
|---|---|---|
| Asset Turnover | 0.77x | 3/8 |
| Fixed Assets Turnover | 18.8x | 2/9 |
Income Statement
| Metric | BIAF | Rank |
|---|---|---|
| Total Revenue | $6M | 7/8 |
| Operating Income | -$12M | 12/15 |
| Net Income | -$15M | 8/12 |
| R&D Expense | $1M | 6/7 |
| SG&A Expense | $11M | 9/12 |
Dividend & Shareholder Information
| Metric | BIAF | Rank |
|---|---|---|
| Shares Outstanding | 1M | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $4M | 50.8% of assets |
| Cash & Short-term Investments | $2M | 31.9% of assets |
| Inventory | $80K | 1.0% of assets |
| Total Liabilities | $4M | 50.5% of assets |
| Short-term Debt | $2M | 22.4% of assets |
Quarterly Financial Reports
BIAF quarterly financials and insider trading
Industry Peers · Services-Commercial Physical & Biological Research
Bioaffinity Technologies, Inc. (BIAF) industry peers
Companies classified under the same SEC industry code as Bioaffinity Technologies, Inc. (Services-Commercial Physical & Biological Research): 16 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| BIAF Bioaffinity Technologies, Inc. | ▼ | $5M |
| IQV Iqvia Holdings Inc. | ▼ | $45.37B |
| INCY Incyte Corp | ▶ | $22.20B |
| MEDP Medpace Holdings, Inc. | ▼ | $17.26B |
| CRL Charles River Laboratories International, Inc. | ▶ | $14.33B |
| ICLR Icon Plc | ▶ | $13.13B |
| ABSI Absci Corp | ▲ | $1.42B |
| OABI Omniab, Inc. | ▲ | $667M |
| NRC Nrc Health | ▲ | $446M |
| MXCT Maxcyte, Inc. | ▲ | $134M |
| ONMD Onemednet Corp | ▲ | $28M |
| VSBC Vitaspring Biomedical Co. Ltd. | ▼ | $7M |
| BUDZ Weed, Inc. | ▲ | $3M |
| ISPC Ispecimen Inc. | ▼ | $2M |
| FOXO Foxo Technologies Inc. | ▼ | $180K |
| CBIH Cannabis Bioscience International Holdings, Inc. | ▼ | N/A |
Where BIAF sits on the market map
Industrial Applications and Services · Services-Commercial Physical & Biological Research
News
Bioaffinity Technologies, Inc. (BIAF) stock news
Bioaffinity Technologies, Inc. Presents New Perspectives on Cypath Lung?S Use for Cancer Risk Assessment At Chest 2026 and Discusses Positive Research Data in Development of ...
Affinity Technologies, Inc. will sponsor a Learning Theater presentation at CHEST 2026, the annual meeting of the American College of Chest Physicians, on the evolving role of CyPath® Lung in ...
BioAffinity Technologies to Present New Perspectives on CyPath® Lung’s Use for Cancer Risk Assessment at CHEST 2026
Chief Medical Officer Gordon Downie, MD, to host CHEST 2026 Learning Theater on clinical use of CyPath® Lung Presentation to address current challenges in pulmonary nodule management and to discuss ...
FAQ
Bioaffinity Technologies, Inc. (BIAF) stock forecast FAQ
What is the Bioaffinity Technologies, Inc. (BIAF) stock forecast?
Our AI ranks Bioaffinity Technologies, Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
How accurate are Bioaffinity Technologies, Inc. stock predictions?
For BIAF, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 18.0%, measured on 341 forecast dates between 2022-11-18 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 19.0%, measured on 384 forecast dates between 2022-11-18 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Bioaffinity Technologies, Inc. forecasts updated?
Bioaffinity Technologies, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 16, 2026.
Which companies are Bioaffinity Technologies, Inc.'s industry peers?
16 issuers in our coverage, BIAF included, share the SEC industry code Services-Commercial Physical & Biological Research. The largest are: Iqvia Holdings Inc. (IQV), Incyte Corp (INCY), Medpace Holdings, Inc. (MEDP), Charles River Laboratories International, Inc. (CRL), Icon Plc (ICLR), Absci Corp (ABSI).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.